4.2 Article

Public attitudes regarding a pilot study of newborn screening for spinal muscular atrophy

Journal

AMERICAN JOURNAL OF MEDICAL GENETICS PART A
Volume 161A, Issue 4, Pages 679-686

Publisher

WILEY
DOI: 10.1002/ajmg.a.35756

Keywords

newborn screening; population-based research; public health; spinal muscular atrophy; research ethics; focus groups

Funding

  1. National Institutes of Child Health and Human Development [R01-HD69045]
  2. University of Utah Center for Clinical and Translational Sciences [UL1RR025011]

Ask authors/readers for more resources

A population-based pilot study of newborns screening for a rare genetic condition, spinal muscular atrophy (SMA), is being conducted with funding from the National Institutes of Health. The first component of the study is to assess the ethical, legal, and social implications of population-based pilot studies with a focus on public engagement and parental decision-making for the proposed opt-out approach in this research. We conducted focus groups with members of the general public to ascertain attitudes about the pilot study and acceptability of an opt-out approach in two states, Colorado and Utah, where the pilot screening is being proposed (N=70). We developed an informational video for the project and showed it to the groups prior to the discussion in order to inform participants about population-based research, newborn screening (NBS), permission/consent models, and SMA. Results indicated support for the conduct of pilot studies that is consistent with the current standard of practice for similar population-based programs. There was support for an opt-out approach for parental decision-making; however there was limited parental knowledge about population-based research, NBS and SMA. In general, our participants considered this pilot study to be low risk and of potential benefit to infants and families. The majority of participants were supportive of an opt-out approach with information delivered through various avenues (c) 2013 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Ethnic Studies

Diverse caregivers' HPV vaccine-related awareness and knowledge

Deanna Kepka, Julia Bodson, Djin Lai, Ana C. Sanchez-Birkhead, France A. Davis, Doriena Lee, Fahina Tavake-Pasi, Edwin Napia, Jeannette Villalta, Valentine Mukundente, Ryan Mooney, Heather Coulter, Louisa A. Stark

Summary: The study assessed factors associated with HPV vaccine-related awareness and knowledge among caregivers of adolescents from five ethnic community groups in Utah. Results showed low awareness and knowledge levels among participants, indicating a need for increased education and promotion of HPV vaccine-related issues.

ETHNICITY & HEALTH (2021)

Article Clinical Neurology

Nusinersen in later-onset spinalmuscular atrophy Long-term results from the phase 1/2 studies

Basil T. Darras, Claudia A. Chiriboga, Susan T. Iannaccone, Kathryn J. Swoboda, Jacqueline Montes, Laurence Mignon, Shuting Xia, C. Frank Bennett, Kathie M. Bishop, Jeremy M. Shefner, Allison M. Green, Peng Sun, Ishir Bhan, Sarah Gheuens, Eugene Schneider, Wildon Farwell, Darryl C. De Vivo, Diana Castro, Margaret Cowie, Heather Gilbreath, Shanda Johnson, Melissa Kauk, Muna Khan, Ebra McElroy, Erin Neil Kneirbein, Leslie Nelson, Lauren Smith, Stephanie Trest, Sonya Aziz-Zaman, Joshua Cappell, Andrei Constantinescu, Rosangel Cruz, Jahannaz Dastgir, Sally Dunaway, Nicole Holuba, Alexander G. Khandji, Samantha Kramer, Jonathan Marra, Courtney Ortiz-Miller, Molly Popolizio, Rachel Salazar, Luz Sanabria, Douglas M. Sproule, Louis Weimer, Charles Berde, Ibrahim Binalsheikh, Robert Graham, Peter Kang, Anjali Koka, Mary Landrigan-, Wendy Liew, Jennifer Markowitz, Michael Paldino, Sanjay Prabhu, Navil Sethna, Edward Yang, Russell Butterfield, Deanna DiBella, Melissa Dixon, Summer Gibson, Erin Howard, Breanna Jensen, Nicholas E. Johnson, Donna Lei, Katie Mayne, Kelley J. Murphy, Tara Marie Newcomb, Suyi Niu, Michelle Page, Evan Pucillo, Chris Ramos, Aarati Rao, Nicole M. Rausch, Winter C. Redd, Sandra Reyna Villanueva, James Rian Davis, Ai Sakonji, Abby L. Smart, Susan Sorenson, Austin Stevens, Rachel Tennyson, Donata V. Trussell, Janine L. Wood, Michael J. Workman

NEUROLOGY (2019)

Article Multidisciplinary Sciences

Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development

Sonia M. Vallabh, Chloe K. Nobuhara, Franc Llorens, Inga Zerr, Piero Parchi, Sabina Capellari, Eric Kuhn, Jacob Klickstein, Jiri G. Safar, Flavia C. Nery, Kathryn J. Swoboda, Michael D. Geschwind, Henrik Zetterberg, Steven E. Arnold, Eric Vallabh Minikel, Stuart L. Schreiber

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Review Clinical Neurology

Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps

Mei Baker, Robert Griggs, Barry Byrne, Anne M. Connolly, Richard Finkel, Lucja Grajkowska, Amanda Haidet-Phillips, Laura Hagerty, Robert Ostrander, Lianna Orlando, Kathryn Swoboda, Michael Watson, R. Rodney Howell

JAMA NEUROLOGY (2019)

Article Genetics & Heredity

Refining the phenotype of the THG1L (p.Val55Ala mutation)-related mitochondrial autosomal recessive congenital cerebellar ataxia

Melissa A. Walker, Tally Lerman-Sagie, Kathryn Swoboda, Dorit Lev, Lubov Blumkin

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2019)

Article Clinical Neurology

Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy

Bakri Elsheikh, Wendy King, Juan Peng, Kathy J. Swoboda, Sandra P. Reyna, Bernard LaSalle, Thomas W. Prior, W. David Arnold, John T. Kissel, Stephen J. Kolb

MUSCLE & NERVE (2020)

Article Clinical Neurology

Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy

Christiano R. R. Alves, Ren Zhang, Alec J. Johnstone, Reid Garner, Pann H. Nwe, Jennifer J. Siranosian, Kathryn J. Swoboda

NEUROLOGY (2020)

Article Genetics & Heredity

Detection of SMN1 to SMN2 gene conversion events and partial SMN1 gene deletions using array digital PCR

Deborah L. Stabley, Jennifer Holbrook, Mena Scavina, Thomas O. Crawford, Kathryn J. Swoboda, Katherine M. Robbins, Matthew E. R. Butchbach

Summary: Proximal spinal muscular atrophy (SMA) is an early-onset motor neuron disease caused by deletion or disabling mutations of survival motor neuron 1 (SMN1) and affected by the copy number of paralog SMN2. Array digital PCR (dPCR) can accurately and reliably measure SMN1 and SMN2 copy numbers and detect gene conversion events and partial deletions of SMN1. In SMA, higher SMN2 copy numbers are associated with milder disease severity.

NEUROGENETICS (2021)

Article Clinical Neurology

Increased systemic HSP70B levels in spinal muscular atrophy infants

Eric J. Eichelberger, Christiano R. R. Alves, Ren Zhang, Marco Petrillo, Patrick Cullen, Wildon Farwell, Jessica A. Hurt, John F. Staropoli, Kathryn J. Swoboda

Summary: This study identified HSPA7/HSP70B as a potential novel biomarker for tracking SMA progression, with changes in levels correlating with circulating neurofilament levels in SMA newborns and infants. Further research will determine the response of HSP70B levels to molecular therapies.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Article Biochemistry & Molecular Biology

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni, Kayoko Saito, Jerry R. Mendell, Laurent Servais, Hugh J. McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie A. Parsons, Perry B. Shieh, Sarah Kavanagh, Melissa Wigderson, Sitra Tauscher-Wisniewski, Bryan E. McGill, Thomas A. Macek

Summary: Onasemnogene abeparvovec was effective and well tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.

NATURE MEDICINE (2022)

Article Biochemistry & Molecular Biology

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni, Kayoko Saito, Jerry R. Mendell, Laurent Servais, Hugh J. McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie A. Parsons, Perry B. Shieh, Sarah Kavanagh, Sitra Tauscher-Wisniewski, Bryan E. McGill, Thomas A. Macek

Summary: SPR1NT (NCT03505099) is a Phase III study investigating the efficacy and safety of onasemnogene abeparvovec in presymptomatic children with biallelic SMN1 mutations. The results showed that all 14 infants enrolled in the study were able to sit independently for at least 30 seconds within 18 months and none required permanent ventilation. The treatment was well tolerated and effective for children expected to develop SMA type 1.

NATURE MEDICINE (2022)

Article Clinical Neurology

Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study

Thomas J. Crawford, Kathryn C. Swoboda, Darryl De Vivo, Enrico Bertini, Wuh-Liang S. Hwu, Richard Finkel, Janbernd L. Kirschner, Nancy Kuntz, Aledie Navas A. Nazario, Julie Parsons, Astrid M. Pechmann, M. Monique M. J. Ryan, Russell Butterfield, Haluk Topaloglu, Tawfeg A. Ben-Omran, Valeria Sansone, Yuh-Jyh Jong, Francy Shu, Cong Zhu, Stephanie R. Raynaud, Tiffany D. Lago, Angela Paradis, Richard Foster, Russell Chin, Zdenek Berger, NURTURE Study Grp

Summary: The NURTURE study provides evidence for the effectiveness and safety of early treatment with nusinersen in children with presymptomatic spinal muscular atrophy. The results demonstrate the durability of treatment effects and the potential for improved outcomes in motor function and survival.

MUSCLE & NERVE (2023)

Article Genetics & Heredity

Massachusetts' Findings from Statewide Newborn Screening for Spinal Muscular Atrophy

Jaime E. Hale, Basil T. Darras, Kathryn J. Swoboda, Elicia Estrella, Jin Yun Helen Chen, Mary-Alice Abbott, Beverly N. Hay, Binod Kumar, Anne M. Counihan, Jacalyn Gerstel-Thompson, Inderneel Sahai, Roger B. Eaton, Anne Marie Comeau

Summary: The state of Massachusetts initiated newborn screening for Spinal Muscular Atrophy (SMA) following the availability of new treatment options. The screening identified 9 SMA-affected infants out of 179,467 neonates, with all referred to specialists by day 6 of life. Early data suggests that some SMA-affected children have remained asymptomatic and are meeting developmental milestones, while others have mild to moderate delays.

INTERNATIONAL JOURNAL OF NEONATAL SCREENING (2021)

Article Genetics & Heredity

Impaired kidney structure and function in spinal muscular atrophy

Flavia C. Nery, Jennifer J. Siranosian, Ivy Rosales, Marc-Olivier Deguise, Amita Sharma, Abdurrahman W. Muhtaseb, Pann Nwe, Alec J. Johnstone, Ren Zhang, Maryam Fatouraei, Natassja Huemer, Christiano R. R. Alves, Rashmi Kothary, Kathryn J. Swoboda

NEUROLOGY-GENETICS (2019)

Review Genetics & Heredity

Genotype-structure-phenotype relationships diverge in paralogs ATP1A1, ATP1A2, and ATP1A3

Kathleen J. Sweadner, Elena Arystarkhova, John T. Penniston, Kathryn J. Swoboda, Allison Brashear, Laurie J. Ozelius

NEUROLOGY-GENETICS (2019)

No Data Available